Nerlynx (Neratinib)

Neratinib, the active ingredient in Nerlynx, is a tyrosine kinase inhibitor presented as a oral tablet for oral use. It treats HER2‑positive early‑stage breast cancer in patients who have completed trastuzumab‑based therapy.

GNH USA supplies Nerlynx as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Neratinib is used in the HER2‑positive breast cancer pathway to provide adjuvant benefit after standard therapy.

- HER2‑positive early‑stage breast cancer: reduces risk of disease recurrence following trastuzumab‑based treatment. - Post‑surgical HER2‑positive disease: extends disease‑free survival when given as extended adjuvant therapy. - Patients who have completed trastuzumab: offers additional HER2 blockade to improve long‑term outcomes.

Neratinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: often watery and may require antidiarrheal therapy. - Nausea and vomiting: may be mitigated with antiemetics. - Abdominal pain or cramping. - Fatigue or reduced energy levels. - Decreased appetite or weight loss. - Rash or skin irritation.

Serious or Rare Side Effects: - Elevated liver enzymes (ALT, AST) indicating hepatic injury. - Severe or persistent diarrhea leading to dehydration. - Intestinal perforation or obstruction. - Cardiac dysfunction, including reduced left‑ventricular ejection fraction. - Interstitial lung disease or pneumonitis. - Severe skin reactions such as Stevens‑Johnson syndrome.

Before initiating Neratinib, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline enzymes and repeat periodically. - Diarrhea management: start prophylactic antidiarrheal agents and educate patients. - Cardiac assessment: evaluate baseline cardiac function and monitor during therapy. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks. - Drug‑specific counseling: inform patients about potential gastrointestinal toxicity and the need for prompt reporting. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Neratinib interacts with several drug classes that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise neratinib plasma levels. - Gastric pH‑raising agents (e.g., high‑dose antacids, proton‑pump inhibitors): can reduce absorption. - Concurrent use with other irreversible HER‑family inhibitors: increases risk of overlapping toxicities.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors or inducers (e.g., erythromycin, rifampin): may require dose adjustment. - Anticoagulants (e.g., warfarin): monitor coagulation parameters as neratinib may affect metabolism.